In a regulatory filing late Friday, Agios Pharmaceuticals (NASDAQ: [[ticker:AGIO]]) of Cambridge, MA, reported that chief operating officer Duncan Higgons is leaving the company “to pursue other interests.” Previous to Agios, Higgons was COO of Archemix from 2006 to 2009 and chief commercial officer of Transform Pharmaceuticals from 2002 to 2005. His final day at Agios is Jan. 15.
Author: Alex Lash
I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and Xconomy.
View all posts by Alex Lash
